Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • EVOKE MIND+MATTER BROADENS STRATEGIC CAPABILITY WITH FULL-SERVICE RESEARCH & INSIGHTS OFFERING

    June 17, 2022 |  

    Headed up by Research Director, Angela McMean, the Evoke Mind+Matter Insights division comprises a team of primary research specialists focused on delivering meaningful, data-driven insight that supports the agency’s mission to drive measurable behaviour change.

    Evoke Mind+Matter has continued to strengthen its integrated marcomms offering with the expansion of its in-house market research capabilities.

    Headed up by Research Director, Angela McMean, the Evoke Mind+Matter Insights division comprises a team of primary research specialists focused on delivering meaningful, data-driven insight that supports the agency’s mission to drive measurable behaviour change.

    Angela McMean, Research Director at Evoke Mind+Matter said: “Our team of research experts are specialists in research methodologies and data analytics.  We design and deliver bespoke qualitative and quantitativestudies that include patient, healthcare professional and consumer behaviour analysis, social media and sentiment analysis, market understanding, creative concept and message testing, audience segmentation, real world evidence and communications measurement and evaluation.”

    The Evoke Mind+Matter insights division sits within the strategy team headed up in the UK by Simon Grist, Strategy & Insights Director.

    Simon Grist, UK Strategy & Insights Director at Evoke Mind+Matter said: “We pride ourselves on delivering against our mission to create meaningful experiences that drive meaningful change.  The expansion of our research offering reinforces our commitment to delivering evidence-based strategic programmes built on actionable insights and proven behavioural interventions.”

    Evoke Mind+Matter launched a year ago with a fresh, fearless vision of what healthcare communications could be. It closed 2021 with £6m of new business, 200 per cent growth in average client revenue, 60 new hires, months of investment in a new proprietary tech platform (Gravity.ai) and a unique new proposition to create meaningful experiences driven by data and emotion to ultimately change behaviour.

    This content was provided by Inizio

    Company Details

    - PMLiVE

    Inizio

    Email
    Website

     Latest Content from  Inizio 

    Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series

    Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

    Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

    As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

    How DataGateway unified oncology data for real-world insights & market intelligence

    Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.

    Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.

    Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.

    ESMO 2025 highlights: How storytelling, design & emotion are transforming scientific engagement

    Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders.

    Preparing for ASH 2025: Pharma’s role in hematology innovation

    As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...

    AI without limits: A smarter, integrated approach to Medical Affairs

    At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...

    What to expect from Obesity Week 2025: Key trends shaping the future of obesity care

    Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.

    AI with intent: How Inizio is redefining pharma through precision and partnership

    At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...

    Leading the future of Intelligent Commercialization™: Where proprietary data, tech, and AI meet expert insight

    Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.